PDF下载 ( 2369 KB)
The guideline of prevention and treatment for chronic hepatitis B(2010 version)
-
摘要:
<正>2010年12月10日为规范慢性乙型肝炎的预防、诊断和治疗,中华医学会肝病学分会和感染病学分会于2005年组织国内有关专家制订了《慢性乙型肝炎防治指南》[1]。近
-
Key words:
- hepatitis B /
- chronic /
- treatment /
- prevention
-
[1] 中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南.中华肝脏病杂志,2005,13:881-891. [2]Seeger C,Mason WS.Hepatitis B virus biology.MicrobiolMol Biol Rev,2000,64:51-68. [3]Scaglioni PP,Melegari M,Wands JR.Biologic propertiesof hepatitis B viral genomes with mutations in the precorepromoter and precore open reading frame.Virology,1997,233:374-381. [4]Tran TT,Trinh TN,Abe K.New complex recombinantgenotype of hepatitis B virus identified in Vietnam.J Virol,2008,82:5657-5663. [5]Olinger CM,Jutavijittum P,Hubschen JM,et al.Possiblenew hepatitis B virus genotype,southeast Asia.EmergInfect Dis,2008,14:1777-1780. [6]Chu CJ,Hussain M,Lok AS.Hepatitis B virus genotypeB is associated with earlier HBeAg seroconversioncompared with hepatitis B virus genotype C.Gastroenterology,2002,122:1756-1762. [7] Chu CM,Liaw YF.Genotype C hepatitis B virus infectionis associated with a higher risk of reactivation ofhepatitis B and progression to cirrhosis than genotypeB:a longitudinal study of hepatitis B e antigen-positivepatients with normal aminotransferase levels at baseline.J Hepatol,2005,43:411-417. [8]Yu MW,Yeh SH,Chen PJ,et al.Hepatitis B virusgenotype and DNA level and hepatocellular carcinoma:a prospective study in men.J Natl Cancer Inst,2005,97:265-572. [9]Zhang HW,Yin JH,Li YT,et al.Risk factors for acutehepatitis B and its progression to chronic hepatitis inShanghai,China.Gut,2008,57:1713-1720. [10]Hou J,Schilling R,Janssen HL,et al.Geneticcharacteristics of hepatitis B virus genotypes as a factorfor interferon-induced HBeAg clearance.J Med Virol,2007,79:1055-1063. [11]Jardi R,Rodriguez-Frias F,Schaper M,et al.Analysisof hepatitis B genotype changes in chronic hepatitisB infection:influence of antiviral therapy.J Hepatol,2008,49:695-701. [12]Liu CJ,Kao JH.Genetic variability of hepatitis B virus andresponse to antiviral therapy.Antivir Ther,2008,13:613-624. [13]Ganem D,Prince AM.Hepatitis B virus infection--natural history and clinical consequences.N Engl J Med,2004,350:1118-1129. [14]World Health Organization.Hepatitis B.(Revised August2008)..http://www.who.int/mediacentre/factsheets/fs204/en/[2010-12-9] [15]Liang X,Bi S,Yang W,et al.Epidemiological serosurveyof hepatitis B in China--declining HBV prevalence dueto hepatitis B vaccination.Vaccine,2009,27:6550-6557. [16]Liang X,Bi S,Yang W,et al.Evaluation of the impactof hepatitis B vaccination among children born during1992-2005 in China.J Infect Dis,2009,200:39-47. [17]Lu FM,Zhuang H.Management of hepatitis B in China.Chin Med J(Engl),2009,122:3-4. [18]Mast EE,Margolis HS,Fiore AE,et al.A comprehensiveimmunization strategy to eliminate transmissionof hepatitis B virus infection in the United States:recommendations of the Advisory Committee onImmunization Practices(ACIP)part 1:immunization ofinfants,children,and adolescents.MMWR Recomm Rep,2005,54(RR-16):1-31. [19]World Health Organization.Hepatitis B.http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf[2010-12-9] [20]Lai CL,Ratziu V,Yuen MF,et al.Viral hepatitis B.Lancet,2003,362:2089-2094. [21]Liaw YF.Natural history of chronic hepatitis B virusinfection and long-term outcome under treatment.LiverInt,2009,29 Suppl 1:100-107. [22]Hui CK,Leung N,Yuen ST,et al.Natural history anddisease progression in Chinese chronic hepatitisB patients in immune-tolerant phase.Hepatology,2007,46:395-401. [23]McMahon BJ.The natural history of chronic hepatitis Bvirus infection.Hepatology,2009,49(5 Suppl):S45-55. [24]Liaw YF.Hepatitis flares and hepatitis B e antigenseroconversion:implication in anti-hepatitis B virustherapy.J Gastroenterol Hepatol,2003,18:246-252. [25]Chu CM,Hung SJ,Lin J,et al.Natural history of hepatitisB e antigen to antibody seroconversion in patientswith normal serum aminotransferase levels.Am J Med,2004,116:829-834. [26]Fattovich G,Brollo L,Alberti A,et al.Long-term follow-up of anti-HBe-positive chronic active hepatitis B.Hepatology,1988,8:1651-1654. [27]Brunetto MR,Oliveri F,Rocca G,et al.Natural courseand response to interferon of chronic hepatitis Baccompanied by antibody to hepatitis B e antigen.Hepatology,1989,10:198-202. [28]Di MV,Lo IO,Camma C,et al.The long-term course ofchronic hepatitis B.Hepatology,1999,30:257-264. [29]Chu CM,Liaw YF.Hepatitis B virus-related cirrhosis:natural history and treatment.Semin Liver Dis,2006,26:142-152. [30]Chen YC,Chu CM,Yeh CT,et al.Natural coursefollowing the onset of cirrhosis in patients with chronichepatitis B:a long-term follow-up study.Hepatol Int,2007,1:267-273. [31]Hsu YS,Chien RN,Yeh CT,et al.Long-term outcomeafter spontaneous HBeAg seroconversion in patients withchronic hepatitis B.Hepatology,2002,35:1522-1527. [32]Chou YC,Yu MW,Wu CF,et al.Temporal relationshipbetween hepatitis B virus enhancer II/basal corepromoter sequence variation and risk of hepatocellularcarcinoma.Gut,2008,57:91-97. [33]Chen CJ,Yang HI,Su J,et al.Risk of hepatocellularcarcinoma across a biological gradient of serum hepatitisB virus DNA level.JAMA,2006,295:65-73. [34]Yang HI,Lu SN,Liaw YF,et al.Hepatitis B e antigenand the risk of hepatocellular carcinoma.N Engl J Med,2002,347:168-174. [35]Iloeje UH,Yang HI,Su J,et al.Predicting cirrhosis riskbased on the level of circulating hepatitis B viral load.Gastroenterology,2006,130:678-686. [36]Tai DI,Chen CH,Chang TT,et al.Eight-yearnationwide survival analysis in relatives of patientswith hepatocellular carcinoma:role of viral infection.JGastroenterol Hepatol,2002,17:682-689. [37] 中国疾病预防控制中心.乙型肝炎疫苗儿童计划免疫技术管理规程(试行).2002. [38]夏国良,龚健,王继杰,等.重组乙型肝炎疫苗阻断乙型肝炎病毒母婴传播方案的保护效果评价.中华流行病学杂志,2003,24:362-365. [39]邢玉兰,龚晓红,周绍莲,等.阻断围产期母婴传播最佳免疫方案的研究.中华实验和临床病毒学杂志,1990,4:485-488. [40]Center for Disease Prevention and Control.Breastfeeding.[2010-12-8].http://www.cdc.gov/breastfeeding/disease/hepatitis.htm. [41]World Health Organizaiton.Hepatitis B and Breastfeeding.[2010-12-8].and Breastfeeding.http://www.who.int/child_adolescent_health/documents/pdfs/hepatitis_b_and_breastfeeding.pdf. [42]Zanetti AR,Mariano A,Romano L,et al.Long-termimmunogenicity of hepatitis B vaccination and policyfor booster:an Italian multicentre study.Lancet,2005,366:1379-1384. [43]John TJ,Cooksley G.Hepatitis B vaccine boosters:isthere a clinical need in high endemicity populations.JGastroenterol Hepatol,2005,20:5-10. [44]U.S.Public Health Service.Updated U.S.Public HealthService Guidelines for the Management of OccupationalExposures to HBV,HCV,and HIV and Recommendationsfor Postexposure Prophylaxis.MMWR Recomm Rep,2001,50(RR-11):1-52. [45]中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案.中华肝脏病杂志,2000,8:324-329. [46]Pawlotsky JM,Dusheiko G,Hatzakis A,et al.Virologicmonitoring of hepatitis B virus therapy in clinical trials andpractice:recommendations for a standardized approach.Gastroenterology,2008,134:405-415. [47]Shaheen AA,Wan AF,Myers RP.FibroTest andFibroScan for the prediction of hepatitis C-related fibrosis:a systematic review of diagnostic test accuracy.Am J Gastroenterol,2007,102:2589-2600. [48]Scott DR,Levy MT.Liver transient elastography(Fibr-oscan):a place in the management algorithms of chronicviral hepatitis.Antivir Ther,2010,15:1-11. [49]Lok AS,McMahon BJ.Chronic hepatitis B:update 2009.Hepatology,2009,50:661-662. [50]Lin SM,Yu ML,Lee CM,et al.Interferon therapy inHBeAg positive chronic hepatitis reduces progressionto cirrhosis and hepatocellular carcinoma.J Hepatol,2007,46:45-52. [51]Manesis EK,Hadziyannis SJ.Interferon alpha treatmentand retreatment of hepatitis B e antigen-negativechronic hepatitis B.Gastroenterology,2001,121:101-109. [52]Lau GK,Piratvisuth T,Luo KX,et al.Peginterferon Alfa-2a,lamivudine,and the combination for HBeAg-positivechronic hepatitis B.N Engl J Med,2005,352:2682-2695. [53]Piratvisuth T,Lau G,Chao YC,et al.Sustained responseto peginterferon alfa-2a(40 kD)with or withoutlamivudine in Asian patients with HBeAg-positiveand HBeAg-negative chronic hepatitis B.Hepatol Int,2008,2:102-110. [54]Chan HL,Leung NW,Hui AY,et al.A randomized,controlled trial of combination therapy for chronichepatitis B:comparing pegylated interferon-alpha2band lamivudine with lamivudine alone.Ann Intern Med,2005,142:240-250. [55]Flink HJ,van ZM,Hansen BE,et al.Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitisB:HBsAg loss is associated with HBV genotype.Am JGastroenterol,2006,101:297-303. [56]Buster EH,Flink HJ,Cakaloglu Y,et al.Sustained HBeAgand HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.Gastroenterology,2008,135:459-567. [57]Marcellin P,Lau GK,Bonino F,et al.Peginterferon alfa-2a alone,lamivudine alone,and the two in combinationin patients with HBeAg-negative chronic hepatitis B.NEngl J Med,2004,351:1206-1217. [58]Marcellin P,Bonino F,Lau GK,et al.Sustained responseof hepatitis B e antigen-negative patients 3 years aftertreatment with peginterferon alpha-2a.Gastroenterology,2009,136:2169-2179. [59]Lok AS,McMahon BJ.Chronic hepatitis B.Hepatology,2007,45:507-539. [60]Keeffe EB,Dieterich DT,Han SH,et al.A treatmentalgorithm for the management of chronic hepatitis Bvirus infection in the United States:an update.ClinGastroenterol Hepatol,2006,4:936-962. [61]Fried MW,Piratvisuth T,Lau GK,et al.HBeAg andhepatitis B virus DNA as outcome predictors duringtherapy with peginterferon alfa-2a for HBeAg-positivechronic hepatitis B.Hepatology,2008,47:428-434. [62]Moucari R,Mackiewicz V,Lada O,et al.Early serumHBsAg drop:a strong predictor of sustained virologicalresponse to pegylated interferon alfa-2a in HBeAg-negative patients.Hepatology,2009,49:1151-1157. [63]Brunetto MR,Moriconi F,Bonino F,et al.Hepatitis B virussurface antigen levels:a guide to sustained responseto peginterferon alfa-2a in HBeAg-negative chronichepatitis B.Hepatology,2009,49:1141-1150. [64]Lok AS,Lai CL,Leung N,et al.Long-term safety oflamivudine treatment in patients with chronic hepatitis B.Gastroenterology,2003,125:1714-1722. [65]Lai CL,Chien RN,Leung NW,et al.A one-year trialof lamivudine for chronic hepatitis B.Asia HepatitisLamivudine Study Group.N Engl J Med,1998,339:61-68. [66]Liaw YF,Leung NW,Chang TT,et al.Effects of extendedlamivudine therapy in Asian patients with chronichepatitis B.Asia Hepatitis Lamivudine Study Group.Gastroenterology,2000,119:172-180. [67]Dienstag JL,Schiff ER,Wright TL,et al.Lamivudineas initial treatment for chronic hepatitis B in the UnitedStates.N Engl J Med,1999,341:1256-1263. [68]Chien RN,Liaw YF,Atkins M.Pretherapy alaninetransaminase level as a determinant for hepatitis Be antigen seroconversion during lamivudine therapyin patients with chronic hepatitis B.Asian HepatitisLamivudine Trial Group.Hepatology,1999,30:770-774. [69]Dienstag JL,Goldin RD,Heathcote EJ,et al.Histologicaloutcome during long-term lamivudine therapy.Gastroenterology,2003,124:105-117. [70]Liaw YF,Sung JJ,Chow WC,et al.Lamivudine forpatients with chronic hepatitis B and advanced liverdisease.N Engl J Med,2004,351:1521-1531. [71]Villeneuve JP,Condreay LD,Willems B,et al.Lamivudinetreatment for decompensated cirrhosis resulting fromchronic hepatitis B.Hepatology,2000,31:207-210. [72]Perrillo RP,Wright T,Rakela J,et al.A multicenter United States-Canadian trial to assess lamivudine monotherapybefore and after liver transplantation for chronic hepatitisB.Hepatology,2001,33:424-432. [73]Hann HW,Fontana RJ,Wright T,et al.A United Statescompassionate use study of lamivudine treatment innontransplantation candidates with decompensatedhepatitis B virus-related cirrhosis.Liver Transpl,2003,9:49-56. [74]Jonas MM,Mizerski J,Badia IB,et al.Clinical trial oflamivudine in children with chronic hepatitis B.N Engl JMed,2002,346:1706-1713. [75]Figlerowicz M,Kowala-Piaskowska A,Filipowicz M,etal.Efficacy of lamivudine in the treatment of children withchronic hepatitis B.Hepatol Res,2005,31:217-222. [76]姚光弼,崔振宇,姚集鲁,等.国产拉米夫定治疗2200例慢性乙型肝炎的Ⅳ期临床试验.中华肝脏病杂志,2003,11:103-108. [77]姚光弼,王宝恩,崔振宇,等.拉米夫定治疗慢性乙型肝炎三年疗效观察.中华内科杂志,2003,42:382-387. [78]曾民德,茅益民,姚光弼,等.阿德福韦酯治疗HBeAg阳性的中国慢性乙型病毒性肝炎患者52周的多中心临床研究.中华传染病杂志,2005,23:387-394. [79]Marcellin P,Chang TT,Lim SG,et al.Adefovir dipivoxilfor the treatment of hepatitis B e antigen-positive chronichepatitis B.N Engl J Med,2003,348:808-816. [80]Marcellin P,Chang TT,Lim SG,et al.Long-termefficacy and safety of adefovir dipivoxil for the treatmentof hepatitis B e antigen-positive chronic hepatitis B.Hepatology,2008,48:750-758. [81]Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Long-term therapy with adefovir dipivoxil forHBeAg-negative chronic hepatitis B for up to 5 years.Gastroenterology,2006,131:1743-1751. [82]Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Long-term therapy with adefovir dipivoxil forHBeAg-negative chronic hepatitis B.N Engl J Med,2005,352:2673-2681. [83]Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,etal.Adefovir dipivoxil for the treatment of hepatitis B eantigen-negative chronic hepatitis B.N Engl J Med,2003,348:800-807. [84]Lampertico P,Vigano M,Manenti E,et al.Low resistanceto adefovir combined with lamivudine:a 3-year studyof 145 lamivudine-resistant hepatitis B patients.Gastroenterology,2007,133:1445-1451. [85]Rapti I,Dimou E,Mitsoula P,et al.Adding-on versus switching-to adefovir therapy in lamivudine-resistantHBeAg-negative chronic hepatitis B.Hepatology,2007,45:307-313. [86]Lampertico P,Vigano M,Manenti E,et al.Adefovirrapidly suppresses hepatitis B in HBeAg-negativepatients developing genotypic resistance to lamivudine.Hepatology,2005,42:1414-1419. [87]Peters MG,Hann HH,Martin P,et al.Adefovirdipivoxil alone or in combination with lamivudine inpatients with lamivudine-resistant chronic hepatitis B.Gastroenterology,2004,126:91-101. [88]Perrillo R,Hann HW,Mutimer D,et al.Adefovir dipivoxiladded to ongoing lamivudine in chronic hepatitis Bwith YMDD mutant hepatitis B virus.Gastroenterology,2004,126:81-90. [89]Marzano A,Lampertico P,Mazzaferro V,et al.Prophylaxis of hepatitis B virus recurrence after livertransplantation in carriers of lamivudine-resistantmutants.Liver Transpl,2005,11:532-538. [90]张雅敏,朱志军,郑虹,等.阿德福韦在预防肝移植后乙肝复发中的作用.中华肝胆外科杂志,2006,12:313-315. [91]Chang TT,Gish RG,de Man R,et al.A comparison ofentecavir and lamivudine for HBeAg-positive chronichepatitis B.N Engl J Med,2006,354:1001-1010. [92]Lai CL,Shouval D,Lok AS,et al.Entecavir versuslamivudine for patients with HBeAg-negative chronichepatitis B.N Engl J Med,2006,354:1011-1020. [93]Gish RG,Lok AS,Chang TT,et al.Entecavir therapy forup to 96 weeks in patients with HBeAg-positive chronichepatitis B.Gastroenterology,2007,133:1437-1444. [94]Yokosuka O,Takaguchi K,Fujioka S,et al.Long-term use of entecavir in nucleoside-naive Japanesepatients with chronic hepatitis B infection.J Hepatol,2010,52:791-799. [95]Sherman M,Yurdaydin C,Sollano J,et al.Entecavir fortreatment of lamivudine-refractory,HBeAg-positivechronic hepatitis B.Gastroenterology,2006,130:2039-2049. [96]姚光弼,计焱焱,任红,等.恩替卡韦治疗拉米夫定失效慢性乙型肝炎一年的疗效.中华传染病杂志,2006,24:385-389. [97]姚光弼,朱玫,王宇明,等.恩替卡韦与拉米夫定治疗慢性乙型肝炎随机、双盲、双模拟对照研究.中华内科杂志,2006,45:891-895. [98]Liaw YF,Gane E,Leung N,et al.2-Year GLOBEtrial results:telbivudine Is superior to lamivudine inpatients with chronic hepatitis B.Gastroenterology,2009,136:486-495. [99]Lai CL,Gane E,Liaw YF,et al.Telbivudine versuslamivudine in patients with chronic hepatitis B.N Engl JMed,2007,357:2576-2588. [100]Hou J,Yin YK,Xu D,et al.Telbivudine versus lamivudinein Chinese patients with chronic hepatitis B:Results at1 year of a randomized,double-blind trial.Hepatology,2008,47:447-54. [101]Zeuzem S,Gane E,Liaw YF,et al.Baseline characteri-stics and early on-treatment response predict theoutcomes of 2 years of telbivudine treatment of chronichepatitis B.J Hepatol,2009,51:11-20. [102]贾继东,侯金林,尹有宽,等.替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨.中华肝脏病杂志,2007,15:342-345. [103]Marcellin P,Heathcote EJ,Buti M,et al.Tenofovir diso-proxil fumarate versus adefovir dipivoxil for chronichepatitis B.N Engl J Med,2008,359:2442-2455. [104]Heathcote EJ,Marcellin P,Buti M,et al.Three-year effi-cacy and safety of tenofovir disoproxil fumarate treatmentfor chronic hepatitis B.Gastroenterology,140:132-143. [105]Yuen MF,Fong DY,Wong DK,et al.Hepatitis B virusDNA levels at week 4 of lamivudine treatment predict the5-year ideal response.Hepatology,2007,46:1695-1703. [106]Keeffe EB,Zeuzem S,Koff RS,et al.Report of aninternational workshop:roadmap for management ofpatients receiving oral therapy for chronic hepatitis B.Clin Gastroenterol Hepatol,2007,5:890-897. [107]Chan HL,Tang JL,Tam W,et al.The efficacy of thymosinin the treatment of chronic hepatitis B virus infection:ameta-analysis.Aliment Pharmacol Ther,2001,15:1899-1905. [108]Chien RN,Liaw YF,Chen TC,et al.Efficacy of thymosinalpha1 in patients with chronic hepatitis B:a randomized,controlled trial.Hepatology,1998,27:1383-1387. [109]Hui CK,Cheung WW,Zhang HY,et al.Kineticsand risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.Gastroenterology,2006,131:59-68. [110]中华医学会感染病学分会肝衰竭与人工肝学组和中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南.中华肝脏病杂志,2006,14:643-646. [111]Hung IF,Poon RT,Lai CL,et al.Recurrence of hepatitisB-related hepatocellular carcinoma is associatedwith high viral load at the time of resection.Am JGastroenterol,2008,103:1663-1673. [112]Koda M,Nagahara T,Matono T,et al.Nucleotide analogsfor patients with HBV-related hepatocellular carcinomaincrease the survival rate through improved liver function.Intern Med,2009,48:11-17. [113]Sokal EM,Kelly D,Wirth S,et al.The pharmacokineticsand safety of adefovir dipivoxil in children andadolescents with chronic hepatitis B virus infection.J ClinPharmacol,2008,48:512-517. [114]Lok AS,McMahon BJ.Chronic hepatitis B:update ofrecommendations.Hepatology,2004,39:857-861. -
本文二维码
计量
- 文章访问数: 5344
- HTML全文浏览量: 483
- PDF下载量: 5247
- 被引次数: 0
下载:
